- Board constituted: Deirdre P. Connelly appointed Chair; Pernille Erenbjerg appointed Deputy Chair.
- 5,213 restricted stock units granted at fair value DKK 1,645 each, vesting on the first banking day after a three-year period.
- 4,485 warrants granted with exercise price DKK 1,645, Black‑Scholes value DKK 530.62; warrants vest after three years and expire seven years from grant.
Board constitution
Following the Annual General Meeting on 19 March 2026, Genmab's Board constituted itself: Deirdre P. Connelly was appointed Chair and Pernille Erenbjerg Deputy Chair.
Restricted stock units
The Board approved grants of 5,213 restricted stock units to employees of Genmab and its subsidiaries; each RSU is awarded cost-free and confers a conditional right to one share (nominal DKK 1). Fair value per RSU equals the closing market price at grant, DKK 1,645.00. RSUs vest on the first banking day of the month following a three-year period from the date of grant and are subject to the vesting conditions in the RSU program.
Warrants
The Board approved grants of 4,485 warrants; each warrant is awarded cost-free, entitles the holder to subscribe for one share (nominal DKK 1) at an exercise price of DKK 1,645.00, and has a Black–Scholes fair value of DKK 530.62. Warrants vest three years after grant and expire seven years from the grant date; grants are on the terms of the warrant program adopted 23 February 2021.
